What is Telomir Pharms's earnings per share (EPS)?

Telomir Pharms (TELO) reported diluted earnings per share of $-0.33 for fiscal year 2025. This represents a 41.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Telomir Pharms Financials

TELO

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Telomir Pharms (TELO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Telomir Pharms passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.35x

For every $1 of reported earnings, Telomir Pharms generates $0.35 in operating cash flow (-$3.7M OCF vs -$10.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$10.4M

YoY+37.0%

Telomir Pharms reported -$10.4M in net income in fiscal year 2025. This represents an increase of 37.0% from the prior year.

EPS (Diluted)

$-0.33

YoY+41.1%

Telomir Pharms earned $-0.33 per diluted share (EPS) in fiscal year 2025. This represents an increase of 41.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$7.3M

YoY+475.5%

Telomir Pharms held $7.3M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

34M

YoY+15.5%

Telomir Pharms had 34M shares outstanding in fiscal year 2025. This represents an increase of 15.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-176.1%

YoY+2394.9pp

Telomir Pharms's ROE was -176.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 2394.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$2.4M

YoY+9.0%

Telomir Pharms invested $2.4M in research and development in fiscal year 2025. This represents an increase of 9.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

TELO Income Statement

Metric	FY25	FY24	FY23	FY22
Revenue	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
R&D Expenses	$2.4M+9.0%	$2.2M+42.0%	$1.6M+88.9%	$833K
SG&A Expenses	$8.1M-15.9%	$9.6M+1505.5%	$600K+2766.1%	$21K
Operating Income	N/A	N/A	N/A	N/A
Interest Expense	N/A	$4.3M+164.1%	$1.6M	N/A
Income Tax	N/A	N/A	N/A	N/A
Net Income	-$10.4M+37.0%	-$16.5M-26.5%	-$13.1M-1430.4%	-$854K
EPS (Diluted)	$-0.33+41.1%	$-0.56-216.7%	$0.48+1700.0%	$-0.03

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$760K+1673.0%	$43K-87.3%	$337K	N/A	$627K+5.5%	$595K-26.0%	$804K
SG&A Expenses	N/A	$387K-92.3%	$5.0M+171.6%	$1.9M	N/A	$5.4M+511.4%	$880K+18.6%	$742K
Operating Income	N/A	N/A	N/A	$2.2M	N/A	N/A	N/A	$1.9M
Interest Expense	N/A	N/A	$1K	N/A	N/A	N/A	N/A	$4.3M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$1.1M+78.3%	-$5.1M-132.6%	-$2.2M	N/A	-$6.0M-331.3%	-$1.4M+77.8%	-$6.3M
EPS (Diluted)	N/A	$-0.03-117.6%	$0.17+342.9%	$-0.07	N/A	$-0.20-500.0%	$0.05+121.7%	$-0.23

TELO Balance Sheet

Metric	FY25	FY24	FY23	FY22
Total Assets	$7.3M+454.5%	$1.3M-72.3%	$4.8M+9696.4%	$49K
Current Assets	$7.3M+454.5%	$1.3M+204.2%	$435K+793.1%	$49K
Cash & Equivalents	$7.3M+475.5%	$1.3M+102753.9%	$1K-13.2%	$1K
Inventory	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$1.4M+109.7%	$681K-49.0%	$1.3M+35.5%	$986K
Current Liabilities	$1.4M+109.7%	$681K-49.0%	$1.3M+35.5%	$986K
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	$5.9M+819.6%	$643K-81.3%	$3.4M+466.8%	-$937K
Retained Earnings	-$41.0M-34.0%	-$30.6M-117.6%	-$14.1M-1317.4%	-$992K

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$7.3M-0.8%	$7.4M+792.2%	$830K+68.9%	$491K-62.9%	$1.3M+27.1%	$1.0M-50.4%	$2.1M-40.0%	$3.5M
Current Assets	$7.3M-0.8%	$7.4M+792.2%	$830K+68.9%	$491K-62.9%	$1.3M+27.1%	$1.0M-50.4%	$2.1M-40.0%	$3.5M
Cash & Equivalents	$7.3M-0.6%	$7.3M+871.6%	$754K+87.2%	$403K-68.2%	$1.3M+51.7%	$835K-55.7%	$1.9M-42.5%	$3.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.4M+237.7%	$423K+21.4%	$348K-46.6%	$652K-4.2%	$681K+13.5%	$600K+12.3%	$534K+9.8%	$487K
Current Liabilities	$1.4M+237.7%	$423K+21.4%	$348K-46.6%	$652K-4.2%	$681K+13.5%	$600K+12.3%	$534K+9.8%	$487K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.9M-15.3%	$7.0M+1350.3%	$481K+398.7%	-$161K-125.1%	$643K+45.5%	$442K-72.8%	$1.6M-46.0%	$3.0M
Retained Earnings	-$41.0M-5.3%	-$38.9M-2.9%	-$37.8M-15.5%	-$32.8M-7.1%	-$30.6M-10.5%	-$27.7M-27.2%	-$21.8M-7.1%	-$20.3M

TELO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22
Operating Cash Flow	-$3.7M+27.3%	-$5.1M-31.4%	-$3.9M-723.6%	-$469K
Capital Expenditures	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A
Financing Cash Flow	$9.7M+53.2%	$6.3M+64.1%	$3.9M+721.1%	$470K
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$1.2M-29.6%	-$927K-33.1%	-$696K+19.3%	-$863K-42.5%	-$606K+39.6%	-$1.0M+34.2%	-$1.5M+21.5%	-$1.9M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$1.2M-84.6%	$7.5M	N/A	N/A	$1.0M+2311.3%	-$47K-135.4%	$132K-97.5%	$5.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TELO Financial Ratios

Metric	FY25	FY24	FY23	FY22
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A
Return on Equity	-176.1%+2394.9pp	-2571.0%-2190.8pp	-380.2%	N/A
Return on Assets	-141.8%+1106.8pp	-1248.7%-974.9pp	-273.8%+1479.0pp	-1752.8%
Current Ratio	5.14+3.2	1.94+1.6	0.33+0.3	0.05
Debt-to-Equity	0.24-0.8	1.06+0.7	0.39+1.4	-1.05
FCF Margin	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-15.8%+1037.8pp	-1053.5%	N/A	N/A	-1355.1%-1269.8pp	-85.3%+122.0pp	-207.3%
Return on Assets	N/A	-14.9%+596.2pp	-611.1%-167.3pp	-443.8%	N/A	-574.9%-508.8pp	-66.1%+112.5pp	-178.5%
Current Ratio	5.14-12.4	17.51+15.1	2.38+1.6	0.75-1.2	1.94+0.2	1.74-2.2	3.93-3.3	7.20
Debt-to-Equity	0.24+0.2	0.06-0.7	0.72+4.8	-4.05-5.1	1.06-0.3	1.36+1.0	0.33+0.2	0.16
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Tempest Therapeutics Inc TPST

$22.8M

PepGen Inc PEPG

$119.6M

Acrivon Therapeutics, Inc. ACRV

$58.9M

Radiopharm Theranostics Ltd RADX

$34.7M

CALCIMEDICA INC CALC

$9.2M

Frequently Asked Questions

Is Telomir Pharms profitable?

No, Telomir Pharms (TELO) reported a net income of -$10.4M in fiscal year 2025.

What is Telomir Pharms's return on equity (ROE)?

Telomir Pharms (TELO) has a return on equity of -176.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Telomir Pharms's operating cash flow?

Telomir Pharms (TELO) generated -$3.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Telomir Pharms's total assets?

Telomir Pharms (TELO) had $7.3M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Telomir Pharms spend on research and development?

Telomir Pharms (TELO) invested $2.4M in research and development during fiscal year 2025.

How many shares does Telomir Pharms have outstanding?

Telomir Pharms (TELO) had 34M shares outstanding as of fiscal year 2025.

What is Telomir Pharms's current ratio?

Telomir Pharms (TELO) had a current ratio of 5.14 as of fiscal year 2025, which is generally considered healthy.

What is Telomir Pharms's debt-to-equity ratio?

Telomir Pharms (TELO) had a debt-to-equity ratio of 0.24 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Telomir Pharms's return on assets (ROA)?

Telomir Pharms (TELO) had a return on assets of -141.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Telomir Pharms's cash runway?

Based on fiscal year 2025 data, Telomir Pharms (TELO) had $7.3M in cash against an annual operating cash burn of $3.7M. This gives an estimated cash runway of approximately 24 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Telomir Pharms's Piotroski F-Score?

Telomir Pharms (TELO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Telomir Pharms's earnings high quality?

Telomir Pharms (TELO) has an earnings quality ratio of 0.35x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.